Zeta55, a selective inhibitor of HDAC6, was reported to degrade the androgen receptor (AR) and reduce the growth of AR-overexpressing prostate cancer cells both in vitro and in a castration-resistant prostate cancer (CRPC) xenograft model [51]. Here, HDAC6 is linked to prostate carcinoma.